SILVER SPRING, MD, November 21, 2014 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, and Chief Operating Officer, Gerald W. Crabtree, Ph.D., are in Singapore to finalize the Diabetes Consortium that will
Read more →SILVER SPRING, Md., Nov. 19, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of PharmaCyte Biotech’s pancreatic cancer treatment on the accumulation of ascites fluid
Read more →SILVER SPRING, Md., Nov. 7, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has submitted, through its subsidiary PharmaCyte Biotech Australia, an application to the Therapeutic Goods Administration (TGA) in Australia to obtain the Orphan Drug
Read more →Summary: US company PharmaCyte Biotech has obtained exclusive worldwide rights to use human insulin producing cells developed by UTS’s Professor Ann Simpson and her colleagues The cells could eliminate the need for injections for Type 1 diabetics, a milestone in 20 years’ research to develop the capacity of liver cells to take over the function
Read more →PharmaCyte Biotech, Inc. plans to develop a diabetes treatment using its Cell-in-a-Box® platform technology. In 2013, the company acquired the exclusive worldwide rights to the cellulose-based-live-cell encapsulation technology usage, becoming well positioned to develop treatments for diabetes. Presently, PharmaCyte Biotech has advanced in its development of a line of “live cells” that could be encapsulated
Read more →SILVER SPRING, Md., Oct. 20, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a Collaborative Research Agreement (CRA) with the University of Veterinary Medicine in Vienna, Austria (University). The CRA calls for the
Read more →SILVER SPRING, Md., Oct. 16, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage biotechnology company developing cell and gene therapy solutions for the treatment of diseases, announced today that it has entered into a license with the University of Technology in Sydney, Australia (UTS), that grants PharmaCyte Biotech the worldwide rights to use
Read more →SILVER SPRING, Md., Oct. 13, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage biotechnology company developing cell therapy solutions for the treatment of diseases, announced today that it has submitted an application to the U.S. Food and Drug Administration (FDA) for Orphan Drug Designation for its Cell-in-a-Box(R) treatment for pancreatic cancer. If granted,
Read more →SILVER SPRING, Md., Oct. 6, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that noted European gastroenterologist and oncologist Dr. Matthias Lohr has agreed to serve as Chairman of PharmaCyte Biotech’s newly formed Scientific Advisory Board. Dr. Lohr has been
Read more →SILVER SPRING, Md., Oct. 1, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech, has been appointed Chairman of the Board of Directors and that Prof.
Read more →